In the USA, the CHEK2/T470C variant has been reported in 1.2% of the population, while in Germany, the frequency was 2.2% in breast cancer cases and 0.6% in controls; and in Belarussian population, 5.7% in cases and 1.3% in controls (Bogdanova et al. 2005). Here, CHEK2 is linked to breast carcinoma.